Scientific article
Open access

Amyloid-β positron emission tomography imaging probes: a critical review

Published inJournal of Alzheimer's disease, vol. 36, no. 4, p. 613-631
Publication date2013

The rapidly rising prevalence and cost of Alzheimer's disease in recent decades has made the imaging of amyloid-β deposits the focus of intense research. Several amyloid imaging probes with purported specificity for amyloid-β plaques are currently at various stages of FDA approval. However, a number of factors appear to preclude these probes from clinical utilization. As the available "amyloid specific" positron emission tomography imaging probes have failed to demonstrate diagnostic value and have shown limited utility for monitoring therapeutic interventions in humans, a debate on their significance has emerged. The aim of this review is to identify and discuss critically the scientific issues contributing to the extensive inconsistencies reported in the literature on their purported in vivo amyloid specificity and potential utilization in patients.

  • Alzheimer Disease/radionuclide imaging
  • Amyloid beta-Peptides/diagnostic use
  • Animals
  • Brain/radionuclide imaging
  • Humans
  • Positron-Emission Tomography/methods
  • Radioisotopes/diagnostic use
  • Sensitivity and Specificity
Citation (ISO format)
KEPE, Vladimir et al. Amyloid-β positron emission tomography imaging probes: a critical review. In: Journal of Alzheimer’s disease, 2013, vol. 36, n° 4, p. 613–631. doi: 10.3233/JAD-130485
Main files (1)
Article (Published version)
ISSN of the journal1387-2877

Technical informations

Creation08/06/2014 12:44:00 PM
First validation08/06/2014 12:44:00 PM
Update time03/14/2023 9:45:35 PM
Status update03/14/2023 9:45:35 PM
Last indexation05/02/2024 3:32:39 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack